At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- VX-147 (drug), Placebo (drug)
- How long the study runs
- Study runs about 98 months (dates as stated)
- About the drug or intervention
- VX-147 — drug: Tablets for oral administration. · Placebo — drug: Tablets for oral administration.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 10 Years to 65 Years
- Who
- All
- Number of participants
- 466
- Started
- 2022-03-30
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for proteinuric kidney disease
- • Phase2/Phase3 - 466 participants
- • The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease
Who can take part?
- • Ages 10 Years to 65 Years
- • Diagnosed with proteinuric kidney disease
Where?
- • Basildon - Mid and South Essex Hospitals NHS Trust
- • Bellshill - Synexus Clinical Research - Glasgow (DRS)
- • Birmingham - FutureMeds Birmingham
- • Birmingham - Queen Elizabeth Hospital Birmingham
- • +14 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 10 Years - 65 Years
- Who can join: All genders
What the study is looking for
- ✓Part A:
- ✓APOL1 genotype of G1/G1, G2/G2, or G1/G2
- ✓Proteinuric kidney disease
- ✓Part B:
- ✓\- Completion of Treatment Period in Part A and no permanent discontinuation of the study treatment.
Who cannot take part
- ✗Part A:
- ✗Solid organ or bone marrow transplant
- ✗Uncontrolled hypertension
- ✗History of diabetes mellitus
- ✗Known underlying cause of kidney disease including but not limited to sickle cell disease
See the full criteria
Where Is This Study? (18 UK sites)
Mid and South Essex Hospitals NHS Trust
Basildon, United Kingdom
Synexus Clinical Research - Glasgow (DRS)
Bellshill, United Kingdom
FutureMeds Birmingham
Birmingham, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
Synexus Clinical Research - Midlands (DRS)
Birmingham, United Kingdom
Epsom and St Helier University Hospitals NHS Trust
Carshalton, United Kingdom
Leicester General Hospital
Leicester, United Kingdom
Carolyn Maloney
uhl-tr.researchandinnovationadminmailbox@nhs.net0116 258 8351Great Ormond Street Hospital for Children
London, United Kingdom
Main Email: Research.Governance@gosh.nhs.uk
Research.Governance@gosh.nhs.uk0207 905 2700Guy's Hospital - Endocrinology
London, United Kingdom
King's College Hospital - Pulmonology
London, United Kingdom
Royal Free Hospital - Nephrology
London, United Kingdom
St George's Hospital London - Nephrology
London, United Kingdom
St Pancras Clinical Research
London, United Kingdom
The Royal London Hospital - Nephrology
London, United Kingdom
Manchester Royal Infirmary - Endocrinology
Manchester, United Kingdom
Synexus Clinical Research - NW Consortium Manchester (DRS)
Manchester, United Kingdom
Wythenshawe Hospital - Medicines Evaluation Unit
Manchester, United Kingdom
Nottingham University Hospitals - Children's Clinical Research Facility - Pulmonology
Nottingham, United Kingdom
How to Get in Touch
Medical Information
Sponsor contactCONTACT